Targeted Therapy for Non-Small Cell Lung Cancer with an EGFR Exon 20 Insertion

Clinical Updates In Oncology - 27 Dec 2024Подробнее

Unlocking NSCLC EGFR Gene Mutations Explained!Подробнее

Targeted Therapies for Attacking Non-Small Cell Lung Cancer with Avanish Vellanki Rain TherapeuticsПодробнее

CRSF 7th Masterclass | Exon 20 Insertion Interpretation in Lung Cancer by Dr. Amit Verma | Day 3Подробнее

Decoding Biomarker Testing and Targeted Therapy in NSCLCПодробнее

Meet the Expert on Cancer Treatment updates - 16 Nov 2024Подробнее

CRSF 7th Masterclass | Panel on EGFR & KRAS Therapies: Dr. Akhil Kapoor & Experts DiscussПодробнее

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLCПодробнее

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLCПодробнее

Available Clinical Research in the Care of Patients with NSCLC with an EGFR MutationПодробнее

Understanding Oncogene-Driven Lung Cancer: Targeted Therapy Advances and ChallengesПодробнее

Latest Perspectives for Managing EGFR TKI-Refractory and Resistant Non-Small Cell Lung Cancer: Up...Подробнее

The Molecular Tumor Board: Best Practices for Managing Primary and Acquired EGFR TKI ResistanceПодробнее

Novel Therapies for EGFR Exon 20 Insertions and ALK-Positive NSCLC: Developments and ImplicationsПодробнее

Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerПодробнее

Advances in Oncogene-Driven Metastatic NSCLC: Focusing on EFGR Exon 20 Insertions and ALK-Positiv...Подробнее

Oncology Cancer Treatment Updates 2024 - 22 MayПодробнее

FAVOUR: Furmonertinib in Advanced NSCLC with EGFR Exon 20 Insertions | CRSF 7th Annual Lung CancerПодробнее

Novel Therapies for NSCLC With EGFR Exon 20 Insertions: Practical Pearls for the ClinicПодробнее

Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Karen Reckamp, MD, MSПодробнее